Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.50 |
| ▸ | JUN | P05412 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633430 | 0.91 | MAPK10 (0.48) | MAPK10JUNMAPK8MYLK4STK17A | |
| SCHEMBL1633408 | 0.89 | MAPK10 (0.47) | MAPK10JUNMAPK8LRRK2MYLK4 | |
| SCHEMBL1633941 | 0.88 | LRRK2 (0.43) | MAPK10JUNMAPK8SYKLRRK2 | |
| SCHEMBL1633276 | 0.87 | EGFR (0.50) | MAPK10JUNMAPK8LRRK2TBK1 | |
| SCHEMBL1633459 | 0.87 | SYK (0.46) | MAPK10JUNMAPK8SYKLRRK2 | |
| SCHEMBL13336215 | 0.86 | BRAF (0.41) | MAPK10JUNMAPK8SYKJAK2 | |
| SCHEMBL1868218 | 0.85 | MAPK10 (0.53) | MAPK10JUNMAPK8LRRK2MYLK4 | |
| SCHEMBL13336220 | 0.85 | CDK4 (0.40) | MAPK10JUNMAPK8JAK2CDK4 | |
| SCHEMBL13336105 | 0.85 | BRAF (0.48) | SYK | |
| SCHEMBL1633845 | 0.84 | JUN (0.50) | MAPK10JUNMAPK8SYKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885JUN 544/4885MAPK8 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.